Leukemia

Latest News

Investigators evaluated the impact of low-molecular weight heparin after the first 60 days of treatment as well as treatment overall.
Low-Molecular Weight Heparin Shows No VTE Reduction in Newly Diagnosed ALL

July 10th 2024

Investigators evaluated the impact of low-molecular weight heparin after the first 60 days of treatment as well as treatment overall.

Investigators will assess the clinical activity, safety, and pharmacokinetics of GTB-3650 among those with CD33-expressing cancers in a phase 1 trial.
GTB-3650 Snags FDA Clearance for IND Application in CD33+ Leukemia

July 3rd 2024

Trajectories of Change in Physical Wellbeing Reported for AML Subgroups
Trajectories of Change in Physical Wellbeing Reported for AML Subgroups

June 18th 2024

Phase 3 data from the E1910 trial support the FDA approval of blinatumomab in CD19-positive Philadelphia chromosome–negative B-cell precursor ALL.
FDA Approves Blinatumomab in CD19+ Ph– B-Cell ALL

June 14th 2024

Phase 2a data show no dose-limiting toxicities with SLS009 among patients with relapsed/refractory acute myeloid leukemia.
Phase 2a SLS009 Trial in R/R AML Completes Enrollment and Shows Efficacy

June 11th 2024

More News